Drive Wealth Management LLC Acquires New Holdings in Calidi Biotherapeutics, Inc. (NYSE:CLDI)

Drive Wealth Management LLC acquired a new stake in shares of Calidi Biotherapeutics, Inc. (NYSE:CLDI) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 90,000 shares of the company’s stock, valued at approximately $104,000. Drive Wealth Management LLC owned approximately 0.34% of Calidi Biotherapeutics at the end of the most recent reporting period.

Separately, CPR Investments Inc. boosted its holdings in Calidi Biotherapeutics by 80.4% in the fourth quarter. CPR Investments Inc. now owns 101,000 shares of the company’s stock worth $116,000 after acquiring an additional 45,000 shares in the last quarter. 12.53% of the stock is owned by hedge funds and other institutional investors.

Calidi Biotherapeutics Price Performance

Shares of NYSE CLDI opened at $0.66 on Wednesday. The business has a 50-day simple moving average of $1.51 and a two-hundred day simple moving average of $1.43. Calidi Biotherapeutics, Inc. has a fifty-two week low of $0.62 and a fifty-two week high of $16.80.

Calidi Biotherapeutics (NYSE:CLDI) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.65) earnings per share for the quarter, topping the consensus estimate of ($0.85) by $0.20. As a group, equities research analysts forecast that Calidi Biotherapeutics, Inc. will post -4.48 earnings per share for the current fiscal year.

Calidi Biotherapeutics Company Profile

Calidi Biotherapeutics, Inc, a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors.